has finalized the slump sale of its active pharmaceutical ingredients (API) and formulations business to Cephi Lifesciences Private Limited on November 10, 2025. The transaction included an asset sale and was executed following agreements signed on July 07, 2025. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.